Table 2. Comparison of concomitant drugs used between VA-AKI and No-AKI patients.
| Total n = 665 |
AKI n = 120 |
NO-AKI n = 545 |
P value | |
|---|---|---|---|---|
| Source of VAN, n (%) | 1.000b | |||
| Wenkexin*1 | 655 (98.6) | 119 (99.2) | 536 (98.5) | |
| Laikexin*2 | 9 (1.4) | 1 (0.8) | 8 (1.5) | |
| LOT, n (n) | 1.0 (5.0) | 6.0 (11) | 1.0 (3.0) | 0.000 |
| Mean daily dosage, n (%) | 0.000 | |||
| 0.5 g | 145 (21.9) | 5 (4.2) | 140 (25.8) | |
| 1.0 g | 273 (41.2) | 34 (28.3) | 239 (44.1) | |
| 1.5 g | 40 (6.0) | 13 (10.8) | 27 (5.0) | |
| 2.0 g | 200 (30.2) | 66 (55.0) | 134 (24.7) | |
| 3.0 g | 4 (0.6) | 2 (1.7) | 2 (0.4) | |
| TDM, n (%) | 36 (5.4) | 19 (15.8) | 17 (3.1) | 0.000 |
| Concomitant drugs | ||||
| Vasopressors, n (%) | 56 (8.4) | 38 (31.7) | 18 (3.3) | 0.000 |
| Nitrates, n (%) | 69 (10.4) | 31 (25.8) | 38 (7.0) | 0.000 |
| β-receptor blockers, n (%) | 156 (23.5) | 58 (48.3) | 98 (18.0) | 0.000 |
| Phentolamine, n (%) | 3 (0.5) | 3 (2.5) | 0 (0.0) | 0.006b |
| Amlodipine, n (%) | 123 (18.5) | 21 (17.5) | 102 (18.7) | 0.756 |
| Sodium nitroprusside, n (%) | 3 (0.5) | 3 (2.5) | 0 (0.0) | 0.006b |
| ARBs, n (%) | 44 (6.6) | 7 (5.8) | 37 (6.8) | 0.703 |
| ACEIs, n (%) | 23 (3.5) | 10 (8.3) | 13 (2.4) | 0.001 |
| Aminoglycosides, n (%) | 19 (2.9) | 9 (7.5) | 10 (1.8) | 0.001 |
| Amphotericin B, n (%) | 3 (0.5) | 1 (0.8) | 2 (0.4) | 0.450b |
| Azole antifungals, n (%) | 63 (9.5) | 30 (25.0) | 33 (6.1) | 0.000 |
| Micafungin, n (%) | 39 (5.9) | 20 (16.7) | 19 (3.5) | 0.000 |
| Metronidazole, n (%) | 26 (3.9) | 16 (13.3) | 10 (1.8) | 0.000 |
| Nystatin, n (%) | 24 (3.6) | 15 (12.5) | 9 (1.7) | 0.000 |
| Acyclovir, n (%) | 24 (3.6) | 15 (12.5) | 9 (1.7) | 0.000 |
| Imipenem-cystatins, n (%) | 61 (9.2) | 20 (16.7) | 41 (7.5) | 0.002 |
| β-lactam antibiotics, n (%) | 593 (89.2) | 103 (85.8) | 490 (89.9) | 0.193 |
| Macrolides, n (%) | 19 (2.9) | 11 (9.2) | 8 (1.5) | 0.000 |
| Quinolones, n (%) | 108 (16.2) | 35 (29.2) | 73 (13.4) | 0.000 |
| Sulfonamides, n (%) | 175 (26.3) | 88 (73.3) | 87 (16.0) | 0.000 |
| Tigecycline, n (%) | 4 (0.6) | 2 (1.7) | 2 (0.4) | 0.310a |
| Diuretics, n (%) | 175 (26.3) | 88 (73.3) | 87 (16.0) | 0.000 |
| 20% mannitol, n (%) | 24 (3.6) | 7 (5.8) | 17 (3.1) | 0.149 |
| Low-molecular-weight dextran, n (%) | 19 (2.9) | 0 (0.0) | 19 (3.5) | 0.033b |
| NSAIDs, n (%) | 222 (33.4) | 35 (29.2) | 187 (34.3) | 0.279 |
| Immunosuppressants, n (%) | 20 (3.0) | 13 (10.8) | 7 (1.3) | 0.000 |
| Glucocorticoids, n (%) | 122 (18.3) | 51 (42.5) | 71 (13.0) | 0.000 |
| Chemotherapy drugs, n (%) | 23 (3.5) | 12 (10.0) | 11 (2.0) | 0.000 |
| Contrast medium, n (%) | 22 (3.3) | 15 (12.5) | 7 (1.3) | 0.000 |
| Compound glycyrrhizin, n (%) | 98 (14.7) | 48 (40.0) | 50 (9.2) | 0.000 |
| Compound fresh bamboo juice, n (%) | 17 (2.6) | 6 (5.0) | 11 (2.0) | 0.061 |
| Liquorice tablets, n (%) | 9 (1.4) | 1 (0.8) | 8 (1.5) | 0.914a |
| Ganmao Qingre granules, n (%) | 41 (6.2) | 11 (9.2) | 30 (5.5) | 0.131 |
| Yunnan Baiyao capsules, n (%) | 19 (2.9) | 11 (9.2) | 8 (1.5) | 0.000 |
| Ursodeoxycholic acid, n (%) | 20 (3.0) | 13 (10.8) | 7 (1.3) | 0.000 |
| Simotang, n (%) | 2 (0.3) | 1 (0.8) | 1 (0.2) | 0.329b |
| Qingkailing, n (%) | 2 (0.3) | 1 (0.8) | 1 (0.2) | 0.329b |
| Senna leaf, n (%) | 267 (39.8) | 7 (5.8) | 258 (47.3) | 0.000 |
*1: Trade name: Wenkexin, generic name: Vancomycin Hydrochloride for Injection, manufacturer: Eli Lilly KK Seishin Laboratories, specification: 500 mg/bottle.
*2: Trade name: Laikexin, generic name: Vancomycin Hydrochloride for Injection, manufacturers: Zhejiang Pharmaceutical Co., Ltd. and Xinchang Pharmaceutical Factory, Specification: 500 mg/bottle.